Steroids may be an effective treatment for multiple sclerosis relapses, but they have negative side effects. Continue reading →

November 27, 2019 09:00 ET | Source: Multiple Sclerosis Society of Canada multilang-release TORONTO, Nov. 27, 2019 (GLOBE NEWSWIRE) -- The Multiple Sclerosis (MS) Society of Canada announced today a $1 million donation from TD Bank Group to support research that uses artificial intelligence (AI) to develop clinical tools to enable more informed healthcare decisions in relation to disease-modifying therapies (DMTs) for people with MS. The funds will be directed towards the MS Societys Acts of Greatness campaign Continue reading →

GeNeuro is collaborating with clinical researchers at theKarolinska Institutet and the Academic Specialist Center (ASC) in Stockholm to open a new clinical trial of temelimab in people whosemultiple sclerosis (MS) is progressing in the absence of relapses. Fredrik Piehl, MD, PhD, a professor of neurology at Karolinska and head of research at the MS clinic at ASC, will lead this single-center trial at the ASCs Center for Neurology, the largest MS center in Sweden. Continue reading →

GenentechsOcrevus(ocrelizumab) continues to be the most prescribed medication to reduce inflammatory disease in people with active secondary progressive multiple sclerosis(SPMS) amongU.S. neurologists, even though NovartisMayzent(siponimod) and EMD SeronosMavenclad(cladribine) were approved in March to treat this same MS group, according to a 2019 report bySpherix Global Insights Continue reading →

CBD (cannabidiol), which is one of the popular cannabinoids naturally occurring in the cannabis plant, has become a trendy topic in health and wellness forums. Continue reading →

Patients in England are to get easier access to Merck KGaAs multiple sclerosis drug Mavenclad after NICE dropped requirements for a special MRI scan before prescription. NICE is currently very quiet as like all government bodies it is unable to make public announcements during the purdah period before the December 12 general election. But German Merck said that NICE had issued update guidance on Mavenclad (cladribine tablets) following a fast-tracked guidance update. Continue reading →

CRANBURY, N.J.--(BUSINESS WIRE)--NeurologyLive, a multimedia platform dedicated to providing health care professionals treating neurological diseases with direct access to expert-driven, practice-changing news and insights in neurology, announces the addition of the Consortium of Multiple Sclerosis Centers (CMSC) to its Strategic Alliance Partnership (SAP) program. We are proud to be working with the CMSC, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, parent company of NeurologyLive. CMSC works to improve the lives of all who have been affected by MS by bringing together a society of MS medical professionals Continue reading →

The Progressive Relapsing Multiple Sclerosis Treatment Market Perspective, Comprehensive Analysis along with Major Segments and Forecast, 2019-2025 The Progressive Relapsing Multiple Sclerosis Treatment Market Report provides key strategies followed by leading Progressive Relapsing Multiple Sclerosis Treatment industry manufactures and Sections of Market like- product specifications, volume, production value, Feasibility Analysis, Classification based on types and end user application areas with geographic growth and upcoming advancement. The Progressive Relapsing Multiple Sclerosis Treatment market report provides comprehensive outline of Invention, Industry Requirement, technology and production analysis considering major factors such as Revenue, investments and business growth. Request for sample: https://www.marketinsightsreports.com/reports/02181098761/global-progressive-relapsing-multiple-sclerosis-treatment-market-insights-forecast-to-2025/inquiry?Mode=52 Report includestop leading companies Cognosci Inc, Genzyme Corp, MedImmune LLC, VivaCell Biotechnology Espana SL Global Progressive Relapsing Multiple Sclerosis Treatment Market, By Type COG-133 GZ-402668 Inebilizumab VCE-0032 Others Global Progressive Relapsing Multiple Sclerosis Treatment Market, By Application Clinic Hopital Others Global Progressive Relapsing Multiple Sclerosis Treatment Market Segmentation by Region: North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Malaysia, Philippines, Thailand, Vietnam, Europe, Germany, France, UK, Italy, Russia, Rest of Europe, Central & South America Get Discount on this Report: https://www.marketinsightsreports.com/reports/02181098761/global-progressive-relapsing-multiple-sclerosis-treatment-market-insights-forecast-to-2025/discount?Mode=52 In this study, the years considered to estimate the market size of Progressive Relapsing Multiple Sclerosis Treatment are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025 Browse This Report: https://www.marketinsightsreports.com/reports/02181098761/global-progressive-relapsing-multiple-sclerosis-treatment-market-insights-forecast-to-2025?Mode=52 The report could be customized according to the clients specific research requirements. Continue reading →

Juliana Atieno volunteers in her local health facility as a mentor mother, providing advice and support to pregnant women newly diagnosed with HIV. She is also a passionate advocate for the survivors of gender-based violence and works to ensure that they receive the support and care they deserve, including by linking them to HIV prevention and treatment services. Continue reading →

Twenty-five years ago there were no treatments for multiple sclerosis (MS) a neurological condition that affects more than 100,000 people living in the UK. Continue reading →